Concepedia

Mark J. McPate

MJ

13

Publications

729

Citations

13

H-Index

2005

Active since

Affiliations

University of Bristol(Current)

University of Manchester

Novartis (United Kingdom)

Novartis Institutes for BioMedical Research

Novartis (Switzerland)

Mark J. McPate is an author at University of Bristol specializing in medicine, signal transduction, and cell signaling.

Top concepts

MedicineSignal TransductionCell SignalingPhysiologyPharmacologyCell PhysiologyChannelopathiesElectrophysiologyMolecular PhysiologyPathology

Publications per year

2005–2015

13

Publications

13

The N588K-HERG K+ channel mutation in the ‘short QT syndrome’: Mechanism of gain-in-function determined at 37 °C

Mark J. McPate, Rona S. Duncan, James T. Milnes et al. · Biochemical and Biophysical Research Communications · 2005 · 127 citations

Channelopathies, Signal Transduction, Mendelian Disorder +6

Englerin A Agonizes the TRPC4/C5 Cation Channels to Inhibit Tumor Cell Line Proliferation

Cheryl Carson, Pichai Raman, Jennifer Tullai et al. · PLoS ONE · 2015 · 108 citations · Full text

Trpc4/c5 Cation Channels, Trpc4 Channel, Cancer Biology +16

Pharmacology of the short QT syndrome N588K‐hERG K<sup>+</sup> channel mutation: differential impact on selected class I and class III antiarrhythmic drugs

Mark J. McPate, R S Duncan, JC Hancox et al. · British Journal of Pharmacology · 2008 · 102 citations · Full text

Disopyramide is an effective inhibitor of mutant HERG K+ channels involved in variant 1 short QT syndrome

Mark J. McPate, Rona S. Duncan, Harry J. Witchel et al. · Journal of Molecular and Cellular Cardiology · 2006 · 91 citations

Molecular Pharmacology, Channelopathies, Signal Transduction +7

Increased Vulnerability of Human Ventricle to Re-entrant Excitation in hERG-linked Variant 1 Short QT Syndrome

Ismail Adeniran, Mark J. McPate, Harry J. Witchel et al. · PLoS Computational Biology · 2011 · 68 citations · Full text

Rows per page

1–5 of 13